Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Public ClinicalTrials.gov record NCT03102242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.
Study identification
- NCT ID
- NCT03102242
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2017
- Primary completion
- May 31, 2020
- Completion
- Sep 30, 2022
- Last update posted
- May 23, 2023
2017 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| UCSD Moores Cancer Center | La Jolla | California | 92037 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| EMMC Cancer Care | Brewer | Maine | 04412 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Saint Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Metro MN Community Oncology Research Consortium | Minneapolis | Minnesota | 55416 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Ohio State University James Cancer Center | Columbus | Ohio | 43210 | — |
| Lankenau Medical Center | Wynnewood | Pennsylvania | 19096 | — |
| Prisma Health Greenville Memorial Hospital | Greenville | South Carolina | 29605 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03102242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03102242 live on ClinicalTrials.gov.